December 7, 2021 11:31:28
- 2021 marked Mydecine’s patent application for its MYCO-003 drug candidate
- It also marked notable clinical trials on various aspects, including smoking cessation
- Mydecine also got into a 5-year research agreement with JHU for clinical research on the use of psychedelics for therapeutics
- These milestones have laid down the groundwork, not just for Q3 of the 2021 financial year but also for the company’s growth in the 2022 calendar year
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), since its inception in 2020, has been aiming to transform the treatment of mental health disorders and addiction through biotechnology. The company has already developed first and second-generation novel therapeutics geared towards treating addiction, post-traumatic stress disorder (“PTSD”), and other mental health disorders.
Mydecine recently released its third-quarter 2021 update and a noteworthy announcement for the 2021 calendar year. It offers a glimpse into achievements to date, and what stakeholders can anticipate in the…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at
https://ibn.fm/MYCOF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates
PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit
https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:
https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW?
Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the
InvestorBrandNetwork.